Cancer Treatment Sequencing: How the Order of Therapies Can Influence Outcomes in Modern Oncology

Introduction

Cancer treatment has entered an era in which patients may have access to several different therapeutic approaches, including surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, hormone therapy, cellular therapies, and supportive care. However, having multiple treatment options does not automatically mean that they can be used in any order.

In modern oncology, when a treatment is given can be almost as important as which treatment is given.

This concept is known as cancer treatment sequencing—the strategic planning of therapies in a specific order, combination, or timeframe to achieve the best possible clinical objectives while considering tumor biology, disease stage, treatment response, toxicity, patient characteristics, and long-term goals.

For some cancers, treatment may begin with surgery. For others, therapy may start with systemic treatment before surgery. Radiation may be delivered before or after an operation, while targeted or immune-based treatments may be introduced at particular points in the treatment pathway. In advanced disease, treatment sequences may also change as the cancer responds, progresses, or develops resistance.

The National Cancer Institute defines neoadjuvant therapy as treatment given before the main treatment, usually surgery, while adjuvant therapy refers to additional treatment after primary treatment intended to reduce the risk of recurrence.

As oncology becomes increasingly personalized, treatment sequencing is moving beyond a simple “first treatment, second treatment” model. Clinical teams increasingly consider tumor characteristics, disease stage, treatment goals, patient fitness, previous therapies, expected toxicities, and emerging clinical evidence when developing an individualized treatment pathway.

This article explores why treatment sequencing matters, how different treatment modalities may be ordered, the role of multidisciplinary care, and how research is shaping the future of treatment planning in oncology.

What Is Cancer Treatment Sequencing?

Cancer treatment sequencing refers to the deliberate organization and timing of different cancer therapies throughout a patient's treatment journey.

Instead of viewing surgery, chemotherapy, radiation, immunotherapy, or targeted therapy as isolated interventions, treatment sequencing considers how one therapy may influence the effectiveness, safety, or feasibility of another.

A simplified treatment pathway might look like:

Diagnosis → Staging → Treatment Planning → Initial Therapy → Response Assessment → Additional Therapy → Monitoring

However, real-world cancer care is much more complex.

For example, a patient may receive:

Systemic therapy → Surgery → Radiation → Additional systemic therapy → Surveillance

Another patient with a different cancer may receive:

Surgery → Adjuvant therapy → Surveillance

Meanwhile, a patient with advanced disease may receive:

Systemic therapy → Response assessment → Treatment continuation or modification → Subsequent-line therapy → Supportive care

There is therefore no universal treatment sequence that applies to every cancer.

A treatment plan is developed using information about the disease, treatment goals, available options, potential side effects, expected duration, and follow-up requirements.

 

Why Does the Order of Cancer Treatments Matter?

The order of therapies can influence several aspects of cancer management.

1. Tumor Reduction Before Local Treatment

Some systemic treatments are given before surgery or radiation to reduce tumor burden.

This is the principle behind neoadjuvant therapy. Depending on the cancer, neoadjuvant treatment may include chemotherapy, radiation, hormone therapy, immunotherapy, or combinations of treatments.

Reducing the tumor before surgery may make an operation more feasible in selected patients and can provide information about how the disease responds to therapy.

2. Reducing the Risk of Recurrence

After the primary treatment, additional therapy may be used to address microscopic disease that cannot be detected through conventional clinical evaluation.

This is the purpose of adjuvant therapy in many treatment settings.

Adjuvant treatment may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, biological therapy, or other appropriate treatments depending on the cancer.

3. Preserving Treatment Options

The sequence of therapies can also affect what treatments remain available later.

Some therapies may cause cumulative toxicity. Others may influence organ function, immune status, blood counts, or surgical recovery.

Consequently, oncology teams must consider not only the immediate treatment objective but also the patient's broader treatment journey.

4. Maximizing the Benefit of Combination Approaches

Cancer is biologically complex. A single treatment may not be sufficient for every patient.

Combining modalities can allow clinicians to target cancer through different mechanisms. However, combination strategies require careful consideration of timing, tolerability, interactions, and clinical evidence.

 

Surgery, Radiation and Systemic Therapy: Finding the Right Sequence

Three major pillars of cancer treatment include:

• Surgery
• Radiation therapy
• Systemic therapy

Systemic therapy includes treatments such as chemotherapy, targeted therapy, immunotherapy, and hormone therapy.

The sequence among these approaches varies considerably according to cancer type, stage, molecular characteristics, treatment intent, and patient factors.

Surgery First

In selected localized cancers, surgery may be the initial definitive treatment.

Additional treatment may then be considered based on pathological findings and recurrence risk.

Systemic Therapy Before Surgery

When tumors are larger, locally advanced, or biologically appropriate for preoperative treatment, systemic therapy may be given before surgery.

The goal can include tumor shrinkage, improving surgical feasibility, treating possible microscopic disease early, and evaluating treatment response.

Radiation Before Surgery

For selected cancers, radiation may be used before surgery to reduce local tumor burden or improve local control.

The appropriate approach depends heavily on disease-specific evidence.

Radiation After Surgery

Postoperative radiation may be recommended in particular situations where local recurrence risk warrants additional treatment.

NCI cancer treatment resources describe examples in which therapy before surgery is considered neoadjuvant treatment and treatment after surgery is considered adjuvant treatment.

 

Neoadjuvant vs Adjuvant Therapy

One of the most important concepts in treatment sequencing is the distinction between neoadjuvant and adjuvant therapy.

Neoadjuvant Therapy

Neoadjuvant therapy is given before the main treatment, usually surgery.

Its objectives may include:

• Shrinking the primary tumor
• Treating microscopic disease earlier
• Increasing the feasibility of definitive local treatment
• Assessing treatment response
• Potentially improving surgical outcomes in selected settings

The National Cancer Institute describes neoadjuvant therapy as treatment given as a first step to shrink a tumor before the main treatment, usually surgery.

Adjuvant Therapy

Adjuvant therapy is given after primary treatment, commonly surgery, to reduce the likelihood that cancer will return.

Its role depends on disease type, stage, pathological characteristics, and evidence supporting additional therapy.

The choice between neoadjuvant and adjuvant strategies is not simply a matter of preference. It is determined by disease-specific evidence and individual patient circumstances.

 

Sequencing Chemotherapy in Modern Cancer Care

Chemotherapy may be used at different points in the treatment pathway.

Depending on the cancer, chemotherapy can be used:

• Before surgery
• After surgery
• Together with radiation
• As part of treatment for advanced disease
• In combination with other systemic therapies

NCI notes that chemotherapy can be used to shrink tumors before surgery or radiation, eliminate cancer cells that may remain after local treatment, enhance the effectiveness of other treatments in some settings, and treat cancer that has returned or spread.

The sequence is therefore determined by the therapeutic objective.

For example, chemotherapy before surgery may have a different purpose from chemotherapy given after surgery. In metastatic disease, systemic therapy may instead be the principal treatment approach.

 

Sequencing Radiation Therapy

Radiation therapy can also occupy different positions within a cancer treatment pathway.

Depending on the disease, radiation may be:

• Used before surgery
• Used after surgery
• Combined with systemic therapy
• Used as definitive treatment
• Used for symptom control in advanced cancer

Modern radiation planning can use imaging to define treatment areas and deliver radiation with greater precision while attempting to limit exposure to surrounding normal tissues.

The decision about when radiation should be delivered therefore requires coordination with surgical and medical oncology teams.

 

Sequencing Targeted Therapy

Targeted therapies are designed to act on specific molecular features or pathways associated with cancer.

Their position in a treatment sequence can depend on:

• The molecular profile of the tumor
• Cancer type and stage
• Available approved treatments
• Previous therapy
• Treatment response
• Potential toxicity
• Clinical trial evidence

This is one reason molecular testing can influence treatment planning.

However, molecular information does not automatically determine a single universal sequence. The clinical context remains essential.

 

Sequencing Immunotherapy

Immunotherapy has introduced additional complexity into treatment sequencing.

Checkpoint inhibitors and other immune-based approaches may be used:

• Before surgery
• After surgery
• Together with chemotherapy
• Together with radiation
• In advanced disease
• In combination with other systemic treatments

The optimal sequence may differ between cancers and patient populations.

Recent oncology research continues to examine whether immunotherapy is most beneficial before or after surgery in specific disease settings and how immunotherapy should be integrated with other treatments. ESMO discussions in 2026, for example, highlight continuing uncertainty around optimal sequencing in particular molecularly defined colorectal cancer settings.

This illustrates an important principle: treatment sequencing is an evolving field rather than a fixed formula.

 

Treatment Sequencing Based on Tumor Biology

Modern oncology increasingly recognizes that two patients with the same anatomical cancer type may have biologically different diseases.

Tumor biology can influence treatment decisions through factors such as:

• Histological subtype
• Molecular alterations
• Hormone receptor status
• Immune characteristics
• Disease stage
• Tumor burden
• Previous treatment response

The result is a shift from purely anatomy-based treatment planning toward increasingly individualized strategies.

However, sequencing decisions should not rely on a single biomarker in isolation. Treatment recommendations must be interpreted within the broader clinical context and available evidence.

 

The Role of Treatment Response in Sequencing

Treatment sequencing is not necessarily static.

A patient's treatment plan may change depending on how the tumor responds.

Possible scenarios include:

Good Response

If treatment produces the expected response, the planned sequence may continue.

Stable Disease

If the disease remains stable, clinicians may evaluate whether continuation provides sufficient benefit.

Disease Progression

If cancer progresses during treatment, the clinical team may reconsider the treatment strategy.

Unexpected Toxicity

Treatment may need to be delayed, modified, or changed when toxicity becomes clinically significant.

This creates a dynamic treatment pathway rather than a rigid schedule.

 

Multidisciplinary Cancer Care and Treatment Sequencing

Cancer treatment sequencing often requires collaboration among multiple specialties.

The National Cancer Institute describes multidisciplinary cancer care as involving professionals from different specialties, including medical oncology, surgical oncology, and radiation oncology.

A broader cancer team may include:

• Medical oncologists
• Surgical oncologists
• Radiation oncologists
• Pathologists
• Radiologists
• Genetic specialists
• Pharmacists
• Nurses
• Dietitians
• Physical therapists
• Social workers
• Palliative care professionals

Tumor boards can bring these specialists together to review complex cases and develop treatment plans. NCI describes tumor board review as a process in which cancer specialists meet to discuss cases and determine an appropriate treatment strategy.

ASCO's current oncology care standards similarly emphasize comprehensive team-based care, evidence-based treatment planning, multidisciplinary communication, patient engagement, and quality improvement.

 

Patient Factors That Influence Treatment Sequencing

Treatment sequencing is not determined by tumor characteristics alone.

Important patient-related considerations can include:

Age and Overall Health

Chronological age alone does not determine treatment suitability. Overall health, functional status, and other clinical factors may influence treatment planning.

Organ Function

Kidney, liver, heart, lung, and other organ functions may affect treatment choices.

Previous Treatments

Prior chemotherapy, radiation, surgery, immunotherapy, or targeted therapy can influence subsequent treatment options.

Patient Preferences

Treatment goals and personal preferences are important components of shared decision-making.

Quality of Life

Treatment planning increasingly considers not only disease control but also symptoms, function, treatment burden, and quality of life.

Practical Considerations

Treatment duration, travel, access to specialized care, supportive services, and caregiver availability may also affect implementation.

 

Treatment Sequencing and Clinical Trials

Clinical trials play an important role in determining how new therapies should be incorporated into treatment pathways.

Researchers may investigate whether a therapy works better:

• Before surgery
• After surgery
• In combination with another therapy
• Before or after radiation
• As maintenance treatment
• At first-line treatment
• At later lines of treatment

As evidence accumulates, treatment sequences can change.

ASCO's current guideline priorities demonstrate how rapidly treatment strategies evolve, including ongoing updates addressing neoadjuvant and adjuvant therapies, systemic therapy, immunotherapy, and other disease-specific approaches.

 

The Growing Importance of Clinical Pathways

Another important development is the use of evidence-based oncology clinical pathways.

Clinical pathways can provide structured approaches for managing patients with particular cancer types and stages.

ASCO describes high-quality oncology clinical pathways as detailed, evidence-based treatment protocols designed for specific disease types and stages.

These pathways can help healthcare teams:

• Standardize evidence-based care
• Coordinate multiple treatments
• Reduce unnecessary variation
• Improve communication
• Support treatment planning
• Monitor quality and outcomes

However, clinical pathways should not eliminate individualized decision-making. Patients can have different clinical circumstances even when they share the same diagnosis.

 

Can Treatment Sequencing Help Reduce Resistance?

Cancer treatment resistance remains one of the major challenges in oncology.

Tumors can evolve during treatment, and some cancer cells may survive therapy.

One potential research strategy is to determine whether changing the timing or sequence of therapies can improve disease control.

Researchers are investigating questions such as:

• Should combination treatments be given simultaneously?
• Should one treatment precede another?
• Can early response identify the next optimal therapy?
• Can treatment be adapted based on disease evolution?
• Can different mechanisms of action be strategically combined?

These questions are particularly important as oncology moves toward more dynamic and adaptive treatment approaches.

Importantly, treatment sequencing should not be presented as a guaranteed method of preventing resistance. Its optimal use remains cancer- and context-specific.

 

Treatment Sequencing in Precision Oncology

Precision oncology has expanded the amount of information available for treatment planning.

Genomic and molecular testing can identify alterations that may have therapeutic implications in selected cancers.

But precision oncology is not simply about selecting a drug.

It can also involve deciding:

Which treatment?

For which patient?

At what stage?

In what combination?

In what sequence?

This broader perspective makes treatment sequencing an important component of personalized cancer care.

The Role of Artificial Intelligence in Future Treatment Sequencing

Artificial intelligence is increasingly being investigated across oncology, including clinical decision support, imaging analysis, prediction models, and treatment planning.

In treatment sequencing, future AI systems may potentially help clinicians analyze complex datasets involving:

• Clinical characteristics
• Imaging
• Pathology
• Molecular information
• Treatment history
• Longitudinal response
• Toxicity
• Real-world outcomes

The objective would not be to replace clinicians but to potentially help integrate large amounts of information into more informed decision-making.

However, AI-based sequencing recommendations require rigorous validation, clinical oversight, transparency, and careful assessment of bias before widespread implementation.

 

Challenges in Cancer Treatment Sequencing

Despite significant advances, several challenges remain.

1. Lack of One Universal Sequence

Cancer is heterogeneous. A sequence that works in one cancer may not be appropriate in another.

2. Rapidly Changing Evidence

New clinical trial results can change treatment standards.

3. Treatment Toxicity

The cumulative effects of multiple treatments can limit sequencing options.

4. Patient Heterogeneity

Patients differ in age, comorbidities, functional status, preferences, and ability to tolerate treatment.

5. Access to Care

Advanced therapies and multidisciplinary expertise may not be equally available everywhere.

6. Evidence Gaps

For some emerging combinations and treatment sequences, the optimal order remains uncertain.

These challenges highlight the importance of continuous research and multidisciplinary collaboration.

 

The Future of Cancer Treatment Sequencing

The future of treatment sequencing is likely to become increasingly adaptive, data-driven, and patient-specific.

Instead of developing a complete treatment plan that never changes, oncology may increasingly use a cycle such as:

Plan → Treat → Measure Response → Reassess → Adapt → Continue

Future approaches may integrate:

• Molecular profiling
• Imaging
• Pathology
• Treatment response
• Patient-reported outcomes
• Real-world evidence
• Clinical trial data
• Computational modeling
• Decision-support systems

This could allow treatment strategies to evolve as new information becomes available.

The goal is not simply to use more treatments.

It is to determine the right treatment, for the right patient, at the right time, in the right sequence.

 

Why Treatment Sequencing Matters for Modern Cancer Care

The growing complexity of oncology means that treatment decisions increasingly involve multiple interconnected factors.

A patient may receive several different treatments throughout the cancer journey, but the sequence can influence:

• Treatment feasibility
• Tumor response
• Surgical options
• Toxicity
• Disease control
• Quality of life
• Long-term management

This makes coordinated treatment planning increasingly important.

ASCO's oncology care standards emphasize evidence-based medicine, comprehensive treatment planning, multidisciplinary teamwork, patient engagement, and coordinated care—all of which are relevant to effective treatment sequencing.

Conclusion

Cancer treatment sequencing is becoming an increasingly important component of modern oncology.

As cancer care moves toward more personalized and multimodal treatment strategies, clinicians must consider not only which therapies to use but also when and in what order they should be delivered.

Neoadjuvant and adjuvant therapies illustrate how treatment timing can influence the overall cancer care pathway. Surgery, radiation, chemotherapy, targeted therapy, immunotherapy, and supportive care may each occupy different positions depending on cancer type, disease stage, tumor biology, treatment goals, patient characteristics, and available evidence.

The future of cancer treatment sequencing will likely involve increasingly dynamic decision-making, integrating clinical data, molecular information, treatment response, multidisciplinary expertise, and emerging technologies.

As research continues, better understanding of treatment timing and sequencing could contribute to more coordinated, individualized, and evidence-based cancer care.

 

Join the Global Oncology Community

The International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027) will bring together researchers, oncologists, clinicians, healthcare professionals, academics, and industry experts to discuss emerging developments across oncology and cancer care.

📅 March 25–27, 2027
📍 Osaka, Japan
🌐 Hybrid Event – In-Person & Virtual

The summit provides an international platform for scientific exchange, research presentations, professional networking, and discussion of emerging approaches in cancer research and clinical care.

FAQs

1. What is cancer treatment sequencing?

Cancer treatment sequencing refers to planning the order and timing of different cancer treatments, such as surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, based on the patient's disease and treatment goals.

2. Why is the sequence of cancer treatments important?

The order of treatments can influence treatment effectiveness, toxicity, surgical options, disease control, and overall patient care. The appropriate sequence depends on the cancer type, stage, tumor characteristics, and individual patient factors.

3. What is the difference between neoadjuvant and adjuvant therapy?

Neoadjuvant therapy is given before the primary treatment, often surgery, while adjuvant therapy is given after the primary treatment to help reduce the risk of cancer recurrence.

4. Can chemotherapy be given before surgery?

Yes. In selected cancers, chemotherapy may be used before surgery as part of a neoadjuvant treatment strategy to reduce tumor burden and assess how the cancer responds to treatment.

5. How does immunotherapy fit into cancer treatment sequencing?

Depending on the cancer type and clinical evidence, immunotherapy may be used before surgery, after surgery, in combination with other treatments, or for advanced disease. Its position in the treatment sequence is determined by disease-specific evidence and patient factors.

6. Does tumor biology affect cancer treatment sequencing?

Yes. Molecular characteristics, tumor subtype, disease stage, treatment response, and other biological features can influence which therapies are selected and when they are administered.

7. Can cancer treatment sequencing change during treatment?

Yes. Treatment plans may be adjusted based on tumor response, disease progression, side effects, new clinical information, or changes in the patient's overall condition.

8. Who decides the sequence of cancer treatments?

Cancer treatment sequencing is typically determined by a multidisciplinary healthcare team that may include medical oncologists, surgical oncologists, radiation oncologists, radiologists, pathologists, nurses, and other specialists.

9. What role do clinical trials play in cancer treatment sequencing?

Clinical trials help researchers determine the most effective timing, combination, and order of emerging cancer therapies. Trial results can contribute to changes in future treatment strategies.

10. What is the future of cancer treatment sequencing?

The future is expected to involve increasingly personalized and adaptive treatment strategies that integrate clinical information, molecular data, treatment response, imaging, and multidisciplinary expertise.